Russia In Vitro Fertilization (IVF) Market by End User (Fertility Clinics, Hospitals, Surgical Centers, and Clinical Research Institutes), Cycle Type (Fresh IVF Cycles (Non-donor), Thawed IVF Cycles (Non-donor), and Donor Egg IVF Cycles), Type (Non-intracytoplasmic Sperm Injection (ICSI) IVF Cycles, and ICSI-Assisted IVF Cycles), Drug (Clomiphene Citrate, Aromatase Inhibitors, Gonadotropins & Gonadotropin-releasing Hormone, Follicle-stimulating Hormone, Progesterone, and Others), and Mode of Administration (Oral, Injectable, and Vaginal) - Opportunity Analysis and Industry Forecast, 2014-2022
In vitro fertilization (IVF) is a complex series of procedures used to treat fertility or genetic problems associated with fertility and assist with child conception. During IVF, mature eggs are collected (retrieved) from the ovaries and fertilized by the sperm cell in a laboratory, followed by the implantation of the fertilized egg (embryo) or eggs in the uterus. The Russia IVF market accounted for $398 million in 2015, and is estimated to reach at $641 million by 2022, registering a CAGR of 7.0% from 2016 to 2022.
IVF is a popular treatments that aids couples with infertility problems, single mothers, and the LGBT community to procreate. The Russia IVF market is expected to witness a substantial growth rate in the future, owing to high incidence of infertility cases, emergent trend of delayed pregnancies among women, technological developments in IVF procedures, and increased incidence of gamete donations.
Growth of the market is further augmented by the low-cost clinical settings for IVF treatments in comparison to U.S., UK, and other established markets. Popularity of Russia for medical tourism, owing to advanced IVF facilities and treatment options, supplement the market growth. However, poor reimbursement policies associated with IVF treatment are anticipated to impede the market growth during the forecast period. Furthermore, rise in concern of single parents and same-sex couples in experiencing parenthood through artificial reproductive technology (ART), especially IVF, is expected to present numerous opportunities for market expansion.
The Russia IVF market is segmented based on end user, cycle type, type, drug, and mode of administration. Based on end user, it is divided into fertility clinics, hospitals, surgical centers, and clinical research institutes. The cycle type is classified into fresh IVF cycles (non-donor), thawed IVF cycles (non-donor), and donor egg IVF cycles. Based on type, the market is bifurcated into non-ICSI IVF cycles and ICSI-assisted IVF cycles. On the basis of drug, it is classified into clomiphene citrate, aromatase inhibitors, gonadotropins & gonadotropin-releasing hormone, follicle-stimulating hormone, progesterone, and others. Mode of administration includes oral, injectable, and vaginal modes.
KEY MARKET BENEFITS
By End User
IVF is a popular treatments that aids couples with infertility problems, single mothers, and the LGBT community to procreate. The Russia IVF market is expected to witness a substantial growth rate in the future, owing to high incidence of infertility cases, emergent trend of delayed pregnancies among women, technological developments in IVF procedures, and increased incidence of gamete donations.
Growth of the market is further augmented by the low-cost clinical settings for IVF treatments in comparison to U.S., UK, and other established markets. Popularity of Russia for medical tourism, owing to advanced IVF facilities and treatment options, supplement the market growth. However, poor reimbursement policies associated with IVF treatment are anticipated to impede the market growth during the forecast period. Furthermore, rise in concern of single parents and same-sex couples in experiencing parenthood through artificial reproductive technology (ART), especially IVF, is expected to present numerous opportunities for market expansion.
The Russia IVF market is segmented based on end user, cycle type, type, drug, and mode of administration. Based on end user, it is divided into fertility clinics, hospitals, surgical centers, and clinical research institutes. The cycle type is classified into fresh IVF cycles (non-donor), thawed IVF cycles (non-donor), and donor egg IVF cycles. Based on type, the market is bifurcated into non-ICSI IVF cycles and ICSI-assisted IVF cycles. On the basis of drug, it is classified into clomiphene citrate, aromatase inhibitors, gonadotropins & gonadotropin-releasing hormone, follicle-stimulating hormone, progesterone, and others. Mode of administration includes oral, injectable, and vaginal modes.
KEY MARKET BENEFITS
- This report provides a detailed quantitative analysis of the current trends in the Russia IVF market from 2014 to 2022 to identify the prevailing opportunities.
- Market estimations are based on comprehensive analysis of the key developments in the industry.
- In-depth analysis based on drugs and end users assists to understand the market and the strategic business planning.
- The developmental strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.
By End User
- Fertility Clinics
- Hospitals
- Surgical Centers
- Clinical Research Institutes
- Fresh IVF Cycles (Non-donor)
- Thawed IVF Cycles (Non-donor)
- Donor egg IVF Cycles
- Non-ICSI IVF Cycles
- ICSI-assisted IVF Cycles
- Clomiphene Citrate
- Aromatase Inhibitors
- Gonadotropins & Gonadotropin-releasing Hormone
- Follicle-stimulating Hormone
- Progesterone
- Others
- Oral
- Injectable
- Vaginal
- Ava-Peter Clinic
- MD Medical Group
- IVF Russia Agilent Technologies
- Vitrolife AB
- EMD Serono, Inc.
- Irvine Scientific
- Cooper Surgical, Inc.
- Cook Medical, Inc.
- Thermo Fisher Scientific, Inc.
CHAPTER 1 RUSSIA IVF MARKET
1.1. EUROPE IVF MARKET (REVENUE AND NUMBER OF CYCLES)
1.2. RUSSIA IVF MARKET (REVENUE AND NUMBER OF CYCLES)
1.2.1. Market size and forecast
1.2.2. Russia IVF market, by end user
1.2.2.1. Market size and forecast
1.2.2.2. Fertility clinics
1.2.2.3. Hospitals
1.2.2.4. Surgical centers
1.2.2.5. Clinical research institutes
1.2.3. Russia IVF market, by cycle type
1.2.3.1. Market size and forecast
1.2.3.2. Fresh IVF cycles (non-donor)
1.2.3.3. Thawed IVF cycles (non-donor)
1.2.3.4. Donor egg IVF cycles
1.2.4. Russia IVF market, by type
1.2.4.1. Market size and forecast
1.2.4.2. Non-ICSI IVF cycles
1.2.4.3. ICSI-assisted IVF cycles
1.2.5. Russia IVF market by pharmacological modality
1.2.5.1. Overview
1.2.5.2. Key trends
1.2.5.3. Market size and forecast
1.2.5.4. Duration of therapy
1.2.5.5. Segmentation of drugs for IVF
1.2.5.5.1. Clomiphene citrate
1.2.5.5.2. Aromatase inhibitors
1.2.5.5.3. Gonadotropins & gonadotropin-releasing hormone (GnRH)
1.2.5.5.4. Follicle-stimulating hormone (FSH)
1.2.5.5.5. Progesterone
1.2.5.5.6. Others
1.2.5.6. Mode of administration
1.2.5.6.1. Oral
1.2.5.6.2. Injectable
1.2.5.6.3. Vaginal
1.2.6. Market dynamics
1.2.6.1. Drivers
1.2.6.1.1. Rise in popularity of fertility tourism
1.2.6.1.2. Advanced IVF facilities and treatment options
1.2.6.2. Restraint
1.2.6.2.1. Inadequate reimbursement policies
1.2.7. Regulatory issues, legislations, and authorities
1.2.8. Insurance reimbursement scenario
CHAPTER 2 COMPANY PROFILES
2.1. AVA-PETER CLINIC
2.1.1. Company overview
2.1.2. Company snapshot
2.1.3. Product portfolio
2.2. MD MEDICAL GROUP INVESTMENTS PLC (MD MEDICAL GROUP)
2.2.1. Company overview
2.2.2. Company snapshot
2.2.3. Operating business segments
2.2.4. Product portfolio
2.2.5. Business performance
2.2.6. Key strategic moves and developments
2.3. IVF RUSSIA (THE INTERNATIONAL CENTRE OF THE REPRODUCTIVE MEDICINES)
2.3.1. Company overview
2.3.2. Company snapshot
2.3.3. Operating business segments
1.1. EUROPE IVF MARKET (REVENUE AND NUMBER OF CYCLES)
1.2. RUSSIA IVF MARKET (REVENUE AND NUMBER OF CYCLES)
1.2.1. Market size and forecast
1.2.2. Russia IVF market, by end user
1.2.2.1. Market size and forecast
1.2.2.2. Fertility clinics
1.2.2.3. Hospitals
1.2.2.4. Surgical centers
1.2.2.5. Clinical research institutes
1.2.3. Russia IVF market, by cycle type
1.2.3.1. Market size and forecast
1.2.3.2. Fresh IVF cycles (non-donor)
1.2.3.3. Thawed IVF cycles (non-donor)
1.2.3.4. Donor egg IVF cycles
1.2.4. Russia IVF market, by type
1.2.4.1. Market size and forecast
1.2.4.2. Non-ICSI IVF cycles
1.2.4.3. ICSI-assisted IVF cycles
1.2.5. Russia IVF market by pharmacological modality
1.2.5.1. Overview
1.2.5.2. Key trends
1.2.5.3. Market size and forecast
1.2.5.4. Duration of therapy
1.2.5.5. Segmentation of drugs for IVF
1.2.5.5.1. Clomiphene citrate
1.2.5.5.2. Aromatase inhibitors
1.2.5.5.3. Gonadotropins & gonadotropin-releasing hormone (GnRH)
1.2.5.5.4. Follicle-stimulating hormone (FSH)
1.2.5.5.5. Progesterone
1.2.5.5.6. Others
1.2.5.6. Mode of administration
1.2.5.6.1. Oral
1.2.5.6.2. Injectable
1.2.5.6.3. Vaginal
1.2.6. Market dynamics
1.2.6.1. Drivers
1.2.6.1.1. Rise in popularity of fertility tourism
1.2.6.1.2. Advanced IVF facilities and treatment options
1.2.6.2. Restraint
1.2.6.2.1. Inadequate reimbursement policies
1.2.7. Regulatory issues, legislations, and authorities
1.2.8. Insurance reimbursement scenario
CHAPTER 2 COMPANY PROFILES
2.1. AVA-PETER CLINIC
2.1.1. Company overview
2.1.2. Company snapshot
2.1.3. Product portfolio
2.2. MD MEDICAL GROUP INVESTMENTS PLC (MD MEDICAL GROUP)
2.2.1. Company overview
2.2.2. Company snapshot
2.2.3. Operating business segments
2.2.4. Product portfolio
2.2.5. Business performance
2.2.6. Key strategic moves and developments
2.3. IVF RUSSIA (THE INTERNATIONAL CENTRE OF THE REPRODUCTIVE MEDICINES)
2.3.1. Company overview
2.3.2. Company snapshot
2.3.3. Operating business segments
LIST OF TABLES
TABLE 1. RUSSIA IVF MARKET, VALUE AND VOLUME, 2014-2022 ($MILLION AND THOUSAND CYCLES)
TABLE 2. RUSSIA IVF MARKET VALUE, BY END USER, 2014-2022 ($MILLION)
TABLE 3. RUSSIA IVF MARKET VOLUME, BY END USER, 2014-2022 (THOUSAND CYCLES)
TABLE 4. RUSSIA IVF MARKET VALUE, BY CYCLE TYPE, 2014-2022 ($MILLION)
TABLE 5. RUSSIA IVF MARKET VOLUME, BY CYCLE TYPE, 2014-2022 (THOUSAND CYCLES)
TABLE 6. RUSSIA IVF MARKET VALUE, BY TYPE, 2014-2022 ($MILLION)
TABLE 7. RUSSIA IVF MARKET VALUE, BY DRUG, 2014-2022 ($MILLION)
TABLE 8. RUSSIA IVF MARKET VALUE, BY MODE OF ADMINISTRATION, 2014-2022 ($MILLION)
TABLE 9. CLOMIPHINE CITRATE: KEY BRAND NAMES
TABLE 10. AROMATASE INHIBITORS: KEY BRAND NAMES
TABLE 11. GONADOTROPINS & GNRH: KEY BRAND NAMES
TABLE 12. FSH: KEY BRAND NAMES
TABLE 13. PROGESTERONE: KEY BRAND NAMES
TABLE 14. IVF TREATMENT: KEY ORAL MEDICATIONS
TABLE 15. IVF TREATMENT: KEY INJECTABLE (SUBCUTANEOUS AND INTRAMUSCULAR) MEDICATIONS
TABLE 16. IVF TREATMENT: KEY VAGINAL MEDICATIONS
TABLE 17. AVA PETER CLINIC: COMPANY SNAPSHOT
TABLE 18. AVA PETER CLINICS: PRODUCT PORTFOLIO
TABLE 19. MDMG: COMPANY SNAPSHOT
TABLE 20. MDMG: OPERATING SEGMENTS
TABLE 21. MCRM: COMPANY SNAPSHOT
TABLE 1. RUSSIA IVF MARKET, VALUE AND VOLUME, 2014-2022 ($MILLION AND THOUSAND CYCLES)
TABLE 2. RUSSIA IVF MARKET VALUE, BY END USER, 2014-2022 ($MILLION)
TABLE 3. RUSSIA IVF MARKET VOLUME, BY END USER, 2014-2022 (THOUSAND CYCLES)
TABLE 4. RUSSIA IVF MARKET VALUE, BY CYCLE TYPE, 2014-2022 ($MILLION)
TABLE 5. RUSSIA IVF MARKET VOLUME, BY CYCLE TYPE, 2014-2022 (THOUSAND CYCLES)
TABLE 6. RUSSIA IVF MARKET VALUE, BY TYPE, 2014-2022 ($MILLION)
TABLE 7. RUSSIA IVF MARKET VALUE, BY DRUG, 2014-2022 ($MILLION)
TABLE 8. RUSSIA IVF MARKET VALUE, BY MODE OF ADMINISTRATION, 2014-2022 ($MILLION)
TABLE 9. CLOMIPHINE CITRATE: KEY BRAND NAMES
TABLE 10. AROMATASE INHIBITORS: KEY BRAND NAMES
TABLE 11. GONADOTROPINS & GNRH: KEY BRAND NAMES
TABLE 12. FSH: KEY BRAND NAMES
TABLE 13. PROGESTERONE: KEY BRAND NAMES
TABLE 14. IVF TREATMENT: KEY ORAL MEDICATIONS
TABLE 15. IVF TREATMENT: KEY INJECTABLE (SUBCUTANEOUS AND INTRAMUSCULAR) MEDICATIONS
TABLE 16. IVF TREATMENT: KEY VAGINAL MEDICATIONS
TABLE 17. AVA PETER CLINIC: COMPANY SNAPSHOT
TABLE 18. AVA PETER CLINICS: PRODUCT PORTFOLIO
TABLE 19. MDMG: COMPANY SNAPSHOT
TABLE 20. MDMG: OPERATING SEGMENTS
TABLE 21. MCRM: COMPANY SNAPSHOT
LIST OF FIGURES
FIGURE 1. EUROPE IVF SERVICE MARKET VALUE, 2014-2022 ($MILLION)
FIGURE 2. EUROPE IVF MARKET VOLUME, 2014-2022 (THOUSAND CYCLES)
FIGURE 3. RUSSIA IVF MARKET VALUE FOR FERTILITY CLINICS, 2014-2022 ($MILLION)
FIGURE 4. RUSSIA IVF MARKET VOLUME FOR FERTILITY CLINICS, 2014-2022 (THOUSAND CYCLES)
FIGURE 5. RUSSIA IVF MARKET VALUE FOR HOSPITALS, 2014-2022 ($MILLION)
FIGURE 6. RUSSIA IVF MARKET VOLUME FOR HOSPITALS, 2014-2022 (THOUSAND CYCLES)
FIGURE 7. RUSSIA IVF MARKET VALUE FOR SURGICAL CENTERS, 2014-2022 ($MILLION)
FIGURE 8. RUSSIA IVF MARKET VOLUME FOR SURGICAL CENTERS, 2014-2022 (THOUSAND CYCLES)
FIGURE 9. RUSSIA IVF MARKET VALUE FOR CLINICAL RESEARCH INSTITUTES, 2014-2022 ($MILLION)
FIGURE 10. RUSSIA IVF MARKET VOLUME FOR CLINICAL RESEARCH INSTITUTES 2014-2022 (THOUSAND CYCLES)
FIGURE 11. RUSSIA IVF MARKET VALUE FOR FRESH IVF CYCLES (NON-DONOR), 2014-2022 ($MILLION)
FIGURE 12. RUSSIA IVF MARKET VOLUME FOR FRESH IVF CYCLES (NON-DONOR), 2014-2022 (THOUSAND CYCLES)
FIGURE 13. RUSSIA IVF MARKET VALUE FOR THAWED IVF CYCLES (NON-DONOR), 2014-2022 ($MILLION)
FIGURE 14. RUSSIA IVF MARKET VOLUME FOR THAWED IVF CYCLES (NON-DONOR), 2014-2022 (THOUSAND CYCLES)
FIGURE 15. RUSSIA IVF MARKET VALUE FOR DONOR EGG IVF CYCLES, 2014-2022 ($MILLION)
FIGURE 16. RUSSIA IVF MARKET VOLUME FOR DONOR EGG IVF CYCLES, 2014-2022 (THOUSAND CYCLES)
FIGURE 17. RUSSIA IVF MARKET VALUE FOR NON-ICSE IVF CYCLES, 2014-2022 ( $MILLION)
FIGURE 18. RUSSIA IVF MARKET VALUE FOR ICSE-ASSISTED IVF CYCLES, 2014-2022 ($MILLION)
FIGURE 19. RUSSIA IVF MARKET BY PHARMACOLOGICAL MODALITY
FIGURE 20. RUSSIA IVF MARKET VALUE FOR CLOMIPHINE CITRATE, 2014-2022 ($MILLION)
FIGURE 21. RUSSIA IVF MARKET VALUE FOR AROMATASE INHIBITORS, 2014-2022 ($MILLION)
FIGURE 22. RUSSIA IVF MARKET VALUE FOR GONADOTROPINS AND GNRH, 2014-2022 ($MILLION)
FIGURE 23. RUSSIA IVF MARKET VALUE FOR FSH, 2014-2022 ($MILLION)
FIGURE 24. RUSSIA IVF MARKET VALUE FOR PROGESTERONE, 2014-2022 ($MILLION)
FIGURE 25. RUSSIA IVF MARKET VALUE FOR OTHER DRUGS, 2014-2022 ($MILLION)
FIGURE 26. RUSSIA IVF MARKET VALUE FOR ORAL MODE OF ADMINISTRATION, 2014-2022 ($MILLION)
FIGURE 27. RUSSIA IVF MARKET VALUE FOR INJECTABLE MODE OF ADMINISTRATION, 2014-2022 ($MILLION)
FIGURE 28. RUSSIA IVF MARKET VALUE FOR VAGINAL MODE OF ADMINISTRATION, 2014-2022 ($MILLION)
FIGURE 1. EUROPE IVF SERVICE MARKET VALUE, 2014-2022 ($MILLION)
FIGURE 2. EUROPE IVF MARKET VOLUME, 2014-2022 (THOUSAND CYCLES)
FIGURE 3. RUSSIA IVF MARKET VALUE FOR FERTILITY CLINICS, 2014-2022 ($MILLION)
FIGURE 4. RUSSIA IVF MARKET VOLUME FOR FERTILITY CLINICS, 2014-2022 (THOUSAND CYCLES)
FIGURE 5. RUSSIA IVF MARKET VALUE FOR HOSPITALS, 2014-2022 ($MILLION)
FIGURE 6. RUSSIA IVF MARKET VOLUME FOR HOSPITALS, 2014-2022 (THOUSAND CYCLES)
FIGURE 7. RUSSIA IVF MARKET VALUE FOR SURGICAL CENTERS, 2014-2022 ($MILLION)
FIGURE 8. RUSSIA IVF MARKET VOLUME FOR SURGICAL CENTERS, 2014-2022 (THOUSAND CYCLES)
FIGURE 9. RUSSIA IVF MARKET VALUE FOR CLINICAL RESEARCH INSTITUTES, 2014-2022 ($MILLION)
FIGURE 10. RUSSIA IVF MARKET VOLUME FOR CLINICAL RESEARCH INSTITUTES 2014-2022 (THOUSAND CYCLES)
FIGURE 11. RUSSIA IVF MARKET VALUE FOR FRESH IVF CYCLES (NON-DONOR), 2014-2022 ($MILLION)
FIGURE 12. RUSSIA IVF MARKET VOLUME FOR FRESH IVF CYCLES (NON-DONOR), 2014-2022 (THOUSAND CYCLES)
FIGURE 13. RUSSIA IVF MARKET VALUE FOR THAWED IVF CYCLES (NON-DONOR), 2014-2022 ($MILLION)
FIGURE 14. RUSSIA IVF MARKET VOLUME FOR THAWED IVF CYCLES (NON-DONOR), 2014-2022 (THOUSAND CYCLES)
FIGURE 15. RUSSIA IVF MARKET VALUE FOR DONOR EGG IVF CYCLES, 2014-2022 ($MILLION)
FIGURE 16. RUSSIA IVF MARKET VOLUME FOR DONOR EGG IVF CYCLES, 2014-2022 (THOUSAND CYCLES)
FIGURE 17. RUSSIA IVF MARKET VALUE FOR NON-ICSE IVF CYCLES, 2014-2022 ( $MILLION)
FIGURE 18. RUSSIA IVF MARKET VALUE FOR ICSE-ASSISTED IVF CYCLES, 2014-2022 ($MILLION)
FIGURE 19. RUSSIA IVF MARKET BY PHARMACOLOGICAL MODALITY
FIGURE 20. RUSSIA IVF MARKET VALUE FOR CLOMIPHINE CITRATE, 2014-2022 ($MILLION)
FIGURE 21. RUSSIA IVF MARKET VALUE FOR AROMATASE INHIBITORS, 2014-2022 ($MILLION)
FIGURE 22. RUSSIA IVF MARKET VALUE FOR GONADOTROPINS AND GNRH, 2014-2022 ($MILLION)
FIGURE 23. RUSSIA IVF MARKET VALUE FOR FSH, 2014-2022 ($MILLION)
FIGURE 24. RUSSIA IVF MARKET VALUE FOR PROGESTERONE, 2014-2022 ($MILLION)
FIGURE 25. RUSSIA IVF MARKET VALUE FOR OTHER DRUGS, 2014-2022 ($MILLION)
FIGURE 26. RUSSIA IVF MARKET VALUE FOR ORAL MODE OF ADMINISTRATION, 2014-2022 ($MILLION)
FIGURE 27. RUSSIA IVF MARKET VALUE FOR INJECTABLE MODE OF ADMINISTRATION, 2014-2022 ($MILLION)
FIGURE 28. RUSSIA IVF MARKET VALUE FOR VAGINAL MODE OF ADMINISTRATION, 2014-2022 ($MILLION)
